MAPT and Alzheimer disease: In vitro analyses demonstrated that Stat3 and Fyn inhibitors suppressed AD-related phenotypes of lipopolysaccharide-induced neuroinflammation, tau phosphorylation and Aβ secretion (Roberts et al., 2021).